Kiniksa Pharmaceuticals, Ltd. updated earnings guidance for 2024. For the period, the company expects ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.23 USD | +0.31% | -4.67% | +9.29% |
May. 14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.29% | 1.36B | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.61% | 21.58B | |
-11.18% | 18.96B | |
-40.50% | 16.96B | |
-13.41% | 16.33B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Updates Earnings Guidance for 2024